德琪醫藥的塞利尼索正在中國大陸開展10項用於治療復發或難治性血液腫瘤和晚期實體瘤的臨牀研究
格隆匯12月20日|德琪醫藥-B(6996.HK)在產品獲批投資人電話會議上表示,塞利尼索在中國市場具有廣闊的臨牀應用前景以及擴展至多項適應症的潛力,目前公司正在通過單藥和聯合用藥的方式,同步開展塞利尼索在中國大陸治療復發或難治性血液腫瘤和晚期實體瘤的臨牀研究。
其中包括3項針對復發難治性多發性骨髓瘤(rrMM)和復發難治性瀰漫性大B細胞淋巴瘤(rrDLBCL),已獲美國FDA批准的適應症的中國橋接研究(MARCH研究、BENCH研究和SEARCH研究);3項針對新增適應症的全球性研究;1項針對現有療法無法滿足臨牀需求的亞洲區域高發疾病的TOUCH研究;2項用於治療B細胞非霍奇金淋巴瘤(B-NHL)的新型聯合療法。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.